As federal spending on health care increases in response to the COVID-19 pandemic, including spending on medical devices and diagnostic and laboratory tests, companies should expect close scrutiny from federal prosecutors, particularly where conduct poses a risk to patient health and safety. Few sectors within the health care space have received greater scrutiny from U.S. Department of Justice prosecutors than medical technology companies. We analyzed settlements with such companies (including device manufactures, laboratories and health technology vendors) from 2014 to 2019 and found the following: 67 companies reached settlements totaling more than $1.9 billion in fines, penalties and forfeitures. Kickbacks were the most common type of alleged misconduct, followed by unlawful promotional practices and quality and manufacturing problems. Corporate compliance programs—updated and adapted to address current and emerging risk areas—are essential in mitigating potential actions.

The Years in Numbers: Settlement Statistics

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]